On April 22, Mr. miaozhizhuang, chairman of China Huanan International Group, visited the headquarters of China Resources Sanjiu group in Shenzhen and held business talks with Mr. pandelin, senior director of prescription Business Department of China Resources Sanjiu Pharmaceutical Co., Ltd., on the cooperative development of innovative drugs introduced into China by duer Research Institute of chemical industry.

●Discussion on "research and development of innovative drugs"●

As a long-term strategic partner of China Huanan international, duer Research Institute of chemical industry is a top scientific research institute in the innovative drug R & D industry. It has the internationally leading scientific research technology in the field of "new compounds". It holds a series of drugs that have passed FDA certification. It entrusts China Huanan international to contact domestic drug R & D enterprises, expand the domestic market, and improve the cure rate and treatment quality of this type of drugs in China. The two sides conducted in-depth research and Discussion on the introduction of relevant drugs at various stages, such as the follow-up clinical research application of innovative drugs, phase I clinical trial, phase II clinical trial, phase III clinical trial, new drug application, CFDA approval and listing. This cooperation conforms to the national policy guidance of encouraging the development of domestic innovative drugs, conforms to the medium - and long-term strategy of Cr Sanjiu for the development of innovative drugs, and will further consolidate the development advantages and service capabilities of Cr Sanjiu in the innovative drug industry. It is of great significance for China Huanan international group to expand the big health industry and give full play to its enterprise value.

● the pharmaceutical enterprises' license in transaction situation is good ●

In 2021, China's pharmaceutical enterprises' license in transactions reached a new high, reaching more than 130, and the transaction amount was also rising. Compared with previous years, this year has witnessed more diversified changes, such as more frequent mutual authorization between domestic pharmaceutical enterprises, deeper participation of traditional pharmaceutical enterprises, and earlier and earlier R & D progress.

License in is called license introduction, which can be regarded as a method of drug research and development, because drug research not only has its own research and commissioned research, but also can use the research results of others, who authorize follow-up research and listing in China. License in can also be regarded as a method to introduce drugs. New drugs researched abroad need to meet domestic regulatory requirements and can only be used on the market after being reviewed and approved by relevant domestic departments. This step can be done by foreign enterprises themselves or authorized by foreign enterprises to domestic partners. License in is the last stage of R & D, not without R & D. considering that drug research takes a long time and money, few enterprises have the strength to complete the whole process. Some new generation pharmaceutical enterprises in China put their limited funds and precious energy on the last stage of drug research and development, so as to minimize the risk of research and development.

●Cooperation and sharing●

Director Pan expressed full confidence in the commercial cooperation between China Huanan international group and China Resources Sanjiu group on innovative drugs. It was further pointed out that as one of the key industries of Cr Sanjiu group during the "fourteenth five year plan", innovative drugs will seize the strategic opportunity of industrial development, further accelerate the layout and achieve leapfrog development. This strategic cooperation is an important step towards achieving this goal. It is hoped that the two sides will continue to promote cooperation, accelerate the implementation of projects, and create a successful model of in-depth and strategic cooperation between enterprises.

China Resources Sanjiu Pharmaceutical Co., Ltd

China Resources Sanjiu Pharmaceutical Co., Ltd. (hereinafter referred to as "China Resources Sanjiu") is a large state-owned listed pharmaceutical company, mainly engaged in the R & D, production, sales and related health services of pharmaceutical products. Since its listing, the company has been rated as one of the "top 100 Taurus" and "top 100 value" companies listed on China's main board for many times. Up to now, Cr Sanjiu has been included in Shenzhen stock index, CSI 500, MSCI Emerging Market Index and FTSE Russell.

CR Sanjiu's main core business is positioned in the field of CHC health consumer goods and prescription drugs, with a wide range of products and rich product lines. At present, it has 23 varieties with annual sales of more than 100 million yuan. The "999" brand enjoys high recognition among consumers and the pharmaceutical industry. Over the years, Cr Sanjiu has been listed in the list of "most valuable Chinese brands" released by WPP group; It has continuously ranked among the top in the comprehensive ranking of over-the-counter drug enterprises released by China over the counter drug association, and 999 Ganmaoling granule / capsule has won the first place in cold cough (Chinese patent medicine) for many years.

In the context of the constantly changing environment of the pharmaceutical industry, Cr Sanjiu leads "high-quality development" with innovation, adheres to the two wheel drive of brand + innovation, continues to carry out innovation, transformation and upgrading, strengthens brand and channel construction, increases innovation investment, improves operation quality and efficiency, stabilizes the industry position, and achieves sustained growth in business performance. During the "14th five year plan" strategic period, Cr Sanjiu will target world-class enterprises, improve its business layout, and expand its core business to self diagnosis and treatment; Develop business, focus on pipelines, empower core business, and form a "deep-rooted" business model.

Editor in charge: Zhou Dan

Some pictures are from the official website of China Resources 39

Copyright belongs to the original author

Please let us know if your original copyright is infringed

We will delete the relevant content as soon as possible